ArticleThe Journal of clinical endocrinology and metabolism2023
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly.
Article in The Journal of clinical endocrinology and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Acromegaly complications: an update.The Journal of clinical endocrinology and metabolism · 2026Review
- Association between vertebral fracture risk and bone mineral density in patients with acromegaly.Pituitary · 2025Article
- Vitamin D in the elderly: the phil-rouge in preventing bone, muscle and adipose deterioration?Archives of endocrinology and metabolism · 2025Review
- Acromegaly treatment and bone: a bidirectional relationship.Pituitary · 2025Review
- Prevalence of vertebral fractures in patients with acromegaly: A multicenter cross-sectional study.Hormones (Athens, Greece) · 2025Article
- Vitamin D and hip protectors in osteosarcopenia: a combined hip fracture preventing approach.Reviews in endocrine & metabolic disorders · 2025Review
- Acromegaly and COVID-19, lessons, and new opportunities.Pituitary · 2024Article
- Review
- Vitamin D in pituitary driven osteopathies.Pituitary · 2024Review
- Novel approach to bone comorbidity in resistant acromegaly.Pituitary · 2024Review
- Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes.Pituitary · 2024Review
- Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine reviews · 2024Article
- New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases.Endocrine · 2024Review
- Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly.Journal of neuro-oncology · 2024Article
- GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study.Frontiers in endocrinology · 2024Observational
- Acromegaly and Bone: An Update.Endocrinology and metabolism (Seoul, Korea) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
contextSkeletal fragility is observed in 30% to 60% of acromegaly patients, representing an emerging complication of the disease that increases disability. Despite several studies having investigated the clinical and hormonal prognostic factors for the occurrence of vertebral fractures (VFs) in acromegaly, very few data are available on their prevention/treatment including the effect of vitamin D (VD) supplementation, which has been reported to have a fracture-protective effect in several studies in patients with osteoporosis.
objectiveWe aimed to investigate the role of cholecalciferol (D3) supplementation in the prevention of incident VFs (i-VFs) in acromegaly.
methodsA longitudinal, retrospective and multicenter study was performed on 61 acromegaly patients treated and untreated with D3 supplementation.
resultsTwenty-six patients were treated with D3 supplementation according to clinical guidelines. The median D3 weekly dosage was 8500 IU (interquartile range [IQR]: 3900). The median duration of D3 supplementation was 94 months (IQR: 38). At last follow-up, i-VFs were diagnosed in 14 patients (23%). I-VFs were less prevalent in patients on D3 supplementation (14.3% of cases) compared to patients not treated with D3 (85.7%; P = .02). The final level of serum V25OH-D was significantly lower in patients who developed i-VFs (28.6 ng/mL, IQR: 4.1) compared to patients who did not develop i-VFs (34.2 ng/mL, IQR: 9.6; P = .05). The logistic regression confirmed the protective role of D3 supplementation on the occurrence of i-VFs (odds ratio: 0.16; 95% CI, 0.03-0.79; P = .01).
conclusionIt is likely that D3 supplementation could lead to a reduction in i-VFs in acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.